aTYR PHARMA INC received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
“June 3, 2026, the Company received a letter from the Staff (the “Letter”) notifying the Company that the Company is eligible for an additional 180-day period, or until November 30, 2026 (the “Compliance Date”), to regain compliance, based on the Staff’s determination of the Company meeting the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the minimum bid price requirement, and the Company’s written notice to Nasdaq of its intention to cure the deficiency during the second compl”
Earnings Releases
aTYR PHARMA INC reported financial results for the quarter ended March 31, 2026.
“On May 15, 2026, aTyr Pharma, Inc. issued a press release announcing financial results for the quarter ended March 31, 2026.”
Earnings Releases
aTYR PHARMA INC reported financial results for the year ended December 31, 2025.
“On March 5, 2026, aTyr Pharma, Inc. issued a press release announcing financial results for the year ended December 31, 2025.”
Listing & Compliance Notices
aTYR PHARMA INC received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
“December 4, 2025, aTyr Pharma, Inc. (the “Company”) received a deficiency notice (the “Notice”) from the listing qualifications staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days preceding the date of the Notice, the bid price of the Company’s common stock had closed below $1.00 per share, the minimum closing bid price required by the continued listing requirements of Nasdaq Listing Rule 5550(a)(2). The Notice has no immediate effect on the listing of the Company’s common stock on The Nasdaq Capital Market. In acc”
Earnings Releases
aTYR PHARMA INC reported financial results for the three months ended March 31, 2024.
“On May 2, 2024, aTyr Pharma, Inc. issued a press release announcing financial results for the three months ended March 31, 2024.”
Earnings Releases
aTYR PHARMA INC updated its the year ended December 31, 2023 guidance (reaffirmed).
“SAN DIEGO – March 14, 2024 – aTyr Pharma, Inc. (Nasdaq: LIFE) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced fourth quarter and full year 2023 results and provided a corporate update.”
Earnings Releases
aTYR PHARMA INC updated its the fourth quarter ended December 31, 2023 guidance (reaffirmed).
“SAN DIEGO – March 14, 2024 – aTyr Pharma, Inc. (Nasdaq: LIFE) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced fourth quarter and full year 2023 results and provided a corporate update.”
Earnings Releases
aTYR PHARMA INC updated its third quarter of 2023 guidance (reaffirmed).
“On November 9, 2023, aTyr Pharma, Inc. issued a press release announcing financial results for the quarter ended September 30, 2023.”
Earnings Releases
aTYR PHARMA INC reported financial results for the quarter ended June 30, 2023.
“On August 9, 2023, aTyr Pharma, Inc. issued a press release announcing financial results for the quarter ended June 30, 2023.”
Governance Changes
aTYR PHARMA INC: Board approved and adopted amendments to the Code of Business Conduct and Ethics to augment compliance protections and clarity (effective 2023-05-17).
“On May 17, 2023, the Board adopted and approved certain amendments to the Company’s Code of Business Conduct and Ethics, as reflected in an amended version of the Code of Business Conduct and Ethics (the “Code”).”
Governance Changes
aTYR PHARMA INC: Increased authorized shares of common stock from 85,000,000 to 170,000,000 via Certificate of Amendment to Restated Certificate of Incorporation (effective 2023-05-18).
“On May 18, 2023, following stockholder approval of the Authorized Share Proposal at the Annual Meeting, the Company filed with the Secretary of State of the State of Delaware a Certificate of Amendment to the Company’s Restated Certificate of Incorporation (the “Charter Amendment”) to increase the authorized number of shares of common stock from 85,000,000 to 170,000,000.”
Shareholder Votes
aTYR PHARMA INC shareholders approved Approval of authorization to adjourn the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of Proposals 4 or 5.
“Proposal 6 – Approval of authorization to adjourn the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of Proposals 4 or 5. Votes For Votes Against Abstain Broker Non-Vote 36,384,724 8,179,700 51,768 —”
Shareholder Votes
aTYR PHARMA INC shareholders approved Approval of the Authorized Share Proposal to increase the authorized number of shares of common stock from 85,000,000 to 170,000,000.
“Proposal 5 – Approval of the Authorized Share Proposal to increase the authorized number of shares of common stock from 85,000,000 to 170,000,000. Votes For Votes Against Abstain Broker Non-Vote 41,984,002 518,951 2,113,239 —”
Shareholder Votes
aTYR PHARMA INC shareholders approved Approval of an amendment to the 2015 Stock Plan.
“Proposal 4 – Approval of an amendment to the 2015 Stock Plan. Votes For Votes Against Abstain Broker Non-Vote 30,235,893 8,020,783 42,102 6,317,414”
Shareholder Votes
aTYR PHARMA INC shareholders approved Approval, on an advisory basis, of the compensation of the Company’s named executive officers as disclosed in the Proxy Statement.
“Proposal 3 – Approval, on an advisory basis, of the compensation of the Company’s named executive officers as disclosed in the Proxy Statement. Votes For Votes Against Abstain Broker Non-Vote 37,246,069 1,007,212 45,497 6,317,414”
Shareholder Votes
aTYR PHARMA INC shareholders approved Ratification of the appointment of Ernst and Young LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2023 at the 2023-12-31 meeting.
“Proposal 2 – Ratification of the appointment of Ernst and Young LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2023. Votes For Votes Against Abstain Broker Non-Vote 44,505,484 99,431 11,277 —”
Shareholder Votes
aTYR PHARMA INC shareholders approved Election of two Class II directors.
“Proposal 1 – Election of Class II Directors. Director Nominee Votes For Withhold Broker Non-Vote Timothy P. Coughlin 34,867,452 3,431,326 6,317,414 Jane A. Gross, Ph.D. 34,876,816 3,421,962 6,317,414”
Earnings Releases
aTYR PHARMA INC updated its three months ended March 31, 2023 guidance (reaffirmed).
“On May 9, 2023, aTyr Pharma, Inc. issued a press release announcing financial results for the three months ended March 31, 2023.”
Earnings Releases
aTYR PHARMA INC reported financial results for year ended December 31, 2022.
“On March 9, 2023, aTyr Pharma, Inc. issued a press release announcing financial results for the year ended December 31, 2022.”
Earnings Releases
aTYR PHARMA INC reported financial results for the quarter ended September 30, 2022.
“On November 10, 2022, aTyr Pharma, Inc. issued a press release announcing financial results for the quarter ended September 30, 2022.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.